This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZSAN Zosano Pharma (ZSAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zosano Pharma Stock (NASDAQ:ZSAN) 30 days 90 days 365 days Advanced Chart Get Zosano Pharma alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.52▼$112.0052-Week Range$0.46▼$37.45Volume5,685 shsAverage Volume425,375 shsMarket Capitalization$980.40P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Read More Receive ZSAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZSAN Stock News HeadlinesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.July 14 at 2:00 AM | Brownstone Research (Ad)HOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comEast Bay Business NewsMay 18, 2023 | bizjournals.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comSee More Headlines ZSAN Stock Analysis - Frequently Asked Questions How were Zosano Pharma's earnings last quarter? Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.01. Zosano Pharma had a negative trailing twelve-month return on equity of 177.06% and a negative net margin of 8,375.11%. When did Zosano Pharma's stock split? Zosano Pharma's stock reverse split before market open on Tuesday, April 12th 2022.The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Zosano Pharma IPO? Zosano Pharma (ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. What other stocks do shareholders of Zosano Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zosano Pharma investors own include Tonix Pharmaceuticals (TNXP), NIO (NIO), Adamis Pharmaceuticals (ADMP), Bionano Genomics (BNGO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS). Company Calendar Last Earnings5/13/2022Today7/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZSAN CIK1587221 Webwww.zosanopharma.com Phone(510) 745-1200FaxN/AEmployees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($14.5034) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.92 million Net Margins-8,375.11% Pretax Margin-8,375.11% Return on Equity-177.06% Return on Assets-119.14% Debt Debt-to-Equity RatioN/A Current Ratio1.61 Quick Ratio1.61 Sales & Book Value Annual Sales$790 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.74 per share Price / Book0.00Miscellaneous Outstanding Shares4,902,000Free Float4,784,000Market Cap$980.40 OptionableNot Optionable Beta3.30 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ZSAN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zosano Pharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zosano Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.